Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting

References

• Soleimani VD, Rudnicki MA. New insights into the origin and the genetic basis of rhabdomyosarcomas. Cancer Cell. 2011;19(2):157–13. doi:10.1016/j.ccr.2011.01.044.
   PubMed Web of Science ®Google Scholar
• Lizard-Nacol S, Mugneret F, Volk C, Turc-Carel C, Favrot M, Translocation PT. 2;13)(q37;q14) in alveolar rhabdomyosarcoma: a new case. Cancer Genet Cytogenet. 1987;25(2):373–374. doi:10.1016/0165-4608(87)90202-0.
   PubMedGoogle Scholar
• Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 2002;1(2):97–104. doi:10.4161/cbt.51.
   PubMed Web of Science ®Google Scholar
• Dasgupta R, Fuchs J, Rodeberg D. Rhabdomyosarcoma. Semin Pediatr Surg. 2016;25(5):276–283. doi:10.1053/j.sempedsurg.2016.09.011.
   PubMed Web of Science ®Google Scholar
• Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, Meyer WH, Rodeberg DA, Rudzinski ER, Spunt SL, et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the Children’s Oncology Group. Cancer Med. 2019;8(14):6437–6448. doi:10.1002/cam4.2504.
   PubMed Web of Science ®Google Scholar
• Schwarz H, Tuckwell J, Lotz M. A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene. 1993;134(2):295–298. doi:10.1016/0378-1119(93)90110-O.
   PubMed Web of Science ®Google Scholar
• Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol. 1999;162:5037–5040.
   PubMed Web of Science ®Google Scholar
• Wang S, Chen L. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Curr Top Microbiol Immunol. 2011;344:245–267. doi:10.1007/82_2010_81.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 1999;162(3):5037–5040. doi:10.5483/BMBRep.2014.47.3.283.
   Google Scholar
• Guillerey C, Nakamura K, Pichler AC, Barkauskas D, Krumeich S, Stannard K, Miles K, Harjunpaa H, Yu Y, Casey M, et al. Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. JCI Insight. 2019;5:5. doi:10.1172/jci.insight.125932.
   Google Scholar
• Sanmamed MF, Etxeberria I, Otano I, Melero I. Twists and turns to translating 4-1BB cancer immunotherapy. Sci Transl Med. 2019;11(496):eaax4738.
   Web of Science ®Google Scholar
• Wang KC, Chu KL, Batista NV, Watts TH. Conserved and Differential Features of TNF Superfamily Ligand Expression on APC Subsets over the Course of a Chronic Viral Infection in Mice. Immunohorizons. 2018;2(11):407–417. doi:10.4049/immunohorizons.1800047.
   PubMedGoogle Scholar
• Shao Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol. 2011;89(1):21–29. doi:10.1189/jlb.0510315.
   PubMed Web of Science ®Google Scholar
• Kwajah MMS, Schwarz H. CD137 ligand signaling induces human monocyte to dendritic cell differentiation. Eur J Immunol. 2010;40(7):1938–1949. doi:10.1002/eji.200940105.
   PubMed Web of Science ®Google Scholar
• Harfuddin Z, Kwajah S, Chong Nyi Sim A, Macary PA, Schwarz H. CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses. Oncoimmunology. 2013;2(11):e26859. doi:10.4161/onci.26859.
   PubMed Web of Science ®Google Scholar
• Dharmadhikari B, Nickles E, Harfuddin Z, Ishak NDB, Zeng Q, Bertoletti A, Schwarz H. CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8+ T cells to Tc1 phenotype. CII. 2018;67(6):893–905. doi:10.1007/s00262-018-2144-x.
   Google Scholar
• Zeng Q, Soe YM, Lim Y, Sobota RM, Schwarz H. CD137 ligand interacts with CD32a to trigger reverse CD137 ligand signaling. Cell Mol Immunol. 2020 Nov;17(11):1188-1189.
   Web of Science ®Google Scholar
• Moh MC, Lorenzini PA, Gullo C, Schwarz H. Tumor necrosis factor receptor 1 associates with CD137 ligand and mediates its reverse signaling. FASEB Journal: Official Pub Federat Am Soc Experimen Biol. 2013;27(8):2957–2966. doi:10.1096/fj.12-225250.
   PubMed Web of Science ®Google Scholar
• Setareh M, Schwarz H, Lotz M. A mRNA variant encoding a soluble form of 4-1BB, a member of the murine NGF/TNF receptor family. Gene. 1995;164(2):311–315. doi:10.1016/0378-1119(95)00349-B.
   PubMed Web of Science ®Google Scholar
• Michel J, Langstein J, Hofstadter F, Schwarz H. A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol. 1998;28(1):290–295. doi:10.1002/(SICI)1521-4141(199801)28:01<290::AID-IMMU290>3.0.CO;2-S.
   PubMed Web of Science ®Google Scholar
• Ho WT, Pang WL, Chong SM, Castella A, Al-Salam S, Tan TE, Moh MC, Koh LK, Gan SU, Cheng CK, et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res. 2013;73(2):652–661. doi:10.1158/0008-5472.CAN-12-3849.
   PubMed Web of Science ®Google Scholar
• Anderson MW, Zhao S, Freud AG, Czerwinski DK, Kohrt H, Alizadeh AA, Houot R, Azambuja D, Biasoli I, Morais JC, et al. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol. 2012;181(3):795–803. doi:10.1016/j.ajpath.2012.05.015.
   PubMed Web of Science ®Google Scholar
• Wu M, Wong HY, Lin JL, Moliner A, Schwarz H. Induction of CD137 expression by viral genes reduces T cell costimulation. J Cell Physiol. 2019;234(11):21076–21088. doi:10.1002/jcp.28710.
   PubMed Web of Science ®Google Scholar
• Shao Z, Harfuddin Z, Pang WL, Nickles E, Koh LK, Trogocytic SH. CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation. J Leukoc Biol. 2015;97(5):909–919.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Schwarz H. The role of trogocytosis in immune surveillance of Hodgkin lymphoma. Oncoimmunology. 2020;9(1):1781334. doi:10.1080/2162402X.2020.1781334.
   PubMed Web of Science ®Google Scholar
• Rajendran S, Li Y, Ngoh E, Wong HY, Cheng MS, Wang CI, Schwarz H. Development of a bispecific antibody targeting CD30 and CD137 on Hodgkin and reed-Sternberg cells. Front Oncol. 2019;9:945. doi:10.3389/fonc.2019.00945.
   PubMed Web of Science ®Google Scholar
• Chang KTE, Goytain A, Tucker T, Karsan A, Lee CH, Nielsen TO, Ng TL. Development and evaluation of a pan-sarcoma fusion gene detection assay using the nanostring nCounter platform. JMD. 2018;20(1):63–77. doi:10.1016/j.jmoldx.2017.09.007.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201–210. doi:10.1182/blood-2006-11-056168.
   PubMed Web of Science ®Google Scholar
• Bacher P, Heinrich F, Stervbo U, Nienen M, Vahldieck M, Iwert C, Vogt K, Kollet J, Babel N, Sawitzki B, et al. Regulatory T cell specificity directs tolerance versus allergy against aeroantigens in humans. Cell. 2016;167(4):1067–78 e16. doi:10.1016/j.cell.2016.09.050.
   PubMed Web of Science ®Google Scholar
• Kachapati K, Adams DE, Wu Y, Steward CA, Rainbow DB, Wicker LS, Mittler RS, Ridgway WM. The B10 Idd9.3 locus mediates accumulation of functionally superior CD137+ regulatory T cells in the nonobese diabetic type 1 diabetes Model. J Immunol. 2012;189(10):5001–5015. doi:10.4049/jimmunol.1101013.
   PubMed Web of Science ®Google Scholar
• Kather JN, Horner C, Weis CA, Aung T, Vokuhl C, Weiss C, Scheer M, Marx A, Simon-Keller K. CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. Sci Rep. 2019;9(1):9211. doi:10.1038/s41598-019-45551-y.
   PubMed Web of Science ®Google Scholar
• Dharmadhikari B, Wu M, Abdullah NS, Rajendran S, Ishak ND, Nickles E, Harfuddin Z, Schwarz H. CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology. 2016;5(4):e1113367. doi:10.1080/2162402X.2015.1113367.
   PubMed Web of Science ®Google Scholar
• Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190(2):167–172. doi:10.1006/cimm.1998.1396.
   PubMed Web of Science ®Google Scholar
• Broll K, Richter G, Pauly S, Hofstaedter F, Schwarz H. CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol. 2001;115(4):543–549. doi:10.1309/E343-KMYX-W3Y2-10KY.
   PubMed Web of Science ®Google Scholar
• Wang NP, Marx J, McNutt MA, Rutledge JC, Gown AM. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol. 1995;147:1799–1810.
   PubMed Web of Science ®Google Scholar
• Drenkard D, Becke FM, Langstein J, Spruss T, Kunz-Schughart LA, Tan TE, Lim YC, Schwarz H. CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB Journal: Official Pub Federat Am Soc Experimen Biol. 2007;21(2):456–463. doi:10.1096/fj.05-4739com.
   PubMed Web of Science ®Google Scholar
• Ham B, Fernandez MC, D’Costa Z, Brodt P. The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res. 2016;11:1–27.
   PubMedGoogle Scholar
• Sun X, Guo W, Shen JK, Mankin HJ, Hornicek FJ, Duan Z. Rhabdomyosarcoma: advances in molecular and cellular biology. Sarcoma. 2015;2015:232010. doi:10.1155/2015/232010.
   PubMedGoogle Scholar
• Shao Z, Harfuddin Z, Pang WL, Nickles E, Koh LK, Schwarz H. Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation. J Leukoc Biol. 2015;97(5):909–919. doi:10.1189/jlb.3A0213-079RRR.
   PubMed Web of Science ®Google Scholar
• Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003;4(9):815. doi:10.1038/ni0903-815.
   PubMed Web of Science ®Google Scholar
• Aravinth SP, Rajendran S, Li Y, Wu M, Wong AH, Schwarz H. Epstein–Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed–Sternberg cells via the PI3K-AKT-mTOR pathway. Leuk Lymphoma. 2019;60(11):2697–2704. doi:10.1080/10428194.2019.1607330.
   PubMed Web of Science ®Google Scholar
• Yoshimori M, Imadome K, Komatsu H, Wang L, Saitoh Y, Yamaoka S, Fukuda T, Kurata M, Koyama T, Shimizu N, et al. CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals. PloS One. 2014;9(11):e112564. doi:10.1371/journal.pone.0112564.
   PubMed Web of Science ®Google Scholar
• Pichler K, Kattan T, Gentzsch J, Kress AK, Taylor GP, Bangham CR, Grassmann R. Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients’ T cells by the viral Tax oncoprotein. Blood. 2008;111(9):4741–4751. doi:10.1182/blood-2007-10-115220.
   PubMed Web of Science ®Google Scholar
• Le NH, Kim C-S, Tu TH, Choi H-S, Kim B-S, Kawada T, Goto T, Park T, Park JH, Yu R. Blockade of 4-1BB and 4-1BBL interaction reduces obesity-induced skeletal muscle inflammation. Mediators Inflamm. 2013;2013:865159. doi:10.1155/2013/865159.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tan W, Wang C. Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial–mesenchymal transition. Onco Targets Ther. 2018;11:3817–3826. doi:10.2147/OTT.S168317.
   PubMed Web of Science ®Google Scholar
• Hartley G, Regan D, Guth A, Dow S. Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α. Cancer Immunol Immunother. 2020;9(1):1781334–35. doi:10.1007/s00262-017-1955-5.
   Google Scholar
• Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4(2):216–231. doi:10.1158/2159-8290.CD-13-0639.
   PubMed Web of Science ®Google Scholar
• Glorieux C, Huang P. Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells. Cancer Communications. 2016;167(1):41. doi:10.1186/s40880-019-0386-4.
   Web of Science ®Google Scholar
• Labiano S, Palazon A, Bolanos E, Azpilikueta A, Sanchez-Paulete AR, Morales-Kastresana A, Quetglas JI, Perez-Gracia JL, Gurpide A, Rodriguez-Ruiz M, et al. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. Oncoimmunology. 2016;5(1):e1062967. doi:10.1080/2162402X.2015.1062967.
   PubMed Web of Science ®Google Scholar
• Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170(6):3369–3376. doi:10.4049/jimmunol.170.6.3369.
   PubMed Web of Science ®Google Scholar
• Long X, Ye Y, Zhang L, Liu P, Yu W, Wei F, Ren X, Yu J. IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review). Int J Oncol. 1995;147(1):5–12. doi:10.3892/ijo.2015.3234.
   Web of Science ®Google Scholar
• Wysoczynski M, Shin DM, Kucia M, Ratajczak MZ. Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications. Int J Cancer. 2010;126(2):371–381. doi:10.1002/ijc.24732.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Signal transduction through homo- or heterodimers of gp130. Stem Cells. 2016;11:37–44.
   Google Scholar
• Narazaki M, Witthuhn BA, Yoshida K, Silvennoinen O, Yasukawa K, Ihle JN, Kishimoto T, Taga T. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A. 2016;11(6):1–27. doi:10.1073/pnas.91.6.2285.
   Google Scholar
• Chen C-L, Loy A, Cen L, Chan C, Hsieh F-C, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer. 2007;7(1):111. doi:10.1186/1471-2407-7-111.
   PubMed Web of Science ®Google Scholar
• Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle RR, Johnson LD, Raynaud FI, et al. Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clinical Cancer Res Offici J Am Associ Can Res. 2013;19(21):5940–5951. doi:10.1158/1078-0432.CCR-13-0850.
   PubMed Web of Science ®Google Scholar
• Xiao H, Bid HK, Chen X, Wu X, Wei J, Bian Y, Zhao C, Li H, Li C, Lin J. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy. PloS One. 2017;12(7):e0180297. doi:10.1371/journal.pone.0180297.
   PubMed Web of Science ®Google Scholar
• Gasparini P, Fortunato O, De Cecco L, Casanova M, Iannó MF, Carenzo A, Centonze G, Milione M, Collini P, Boeri M, et al. Age-related alterations in immune contexture are associated with aggressiveness in rhabdomyosarcoma. Cancers (Basel). 2019;11(9):E1380. doi:10.3390/cancers11091380.
   PubMed Web of Science ®Google Scholar
• Schwarz H, Blanco FJ, von Kempis J, Valbracht J, Lotz M. ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival. Blood. 1996;87(7):2839–2845. doi:10.1182/blood.V87.7.2839.bloodjournal8772839.
   PubMed Web of Science ®Google Scholar
• Michel J, Pauly S, Langstein J, Krammer PH, Schwarz H. CD137-induced apoptosis is independent of CD95. Immunology. 1999;98(1):42–46. doi:10.1046/j.1365-2567.1999.00851.x.
   PubMed Web of Science ®Google Scholar
• Chen C, Dorado Garcia H, Scheer M, Henssen AG. Current and future treatment strategies for rhabdomyosarcoma. Front Oncol. 2019;8:1458. doi:10.3389/fonc.2019.01458.
   Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72. doi:10.1146/annurev-immunol-032712-100008.
   PubMed Web of Science ®Google Scholar